ABSTRACT
Continuing recalcitrance to therapy cements pancreatic cancer (PC) as the most lethal malignancy, which is set to become the second leading cause of cancer death in our society.
We interrogated the transcriptome, genome, proteome and functional characteristics of 61 novel PC patient-derived cell lines to define novel therapeutic strategies targeting the DNA damage response (DDR) and replication stress. We show that patient-derived cell lines faithfully recapitulate the epithelial component of pancreatic tumors including previously described molecular subtypes. Biomarkers of DDR deficiency, including a novel signature of homologous recombination deficiency, co-segregates with response to platinum and PARP inhibitor therapy in vitro and in vivo. We generated a novel signature of replication stress with potential clinical utility in predicting response to ATR and WEE1 inhibitor treatment. Replication stress and DDR deficiency are independent of each other, creating opportunities for therapy in DDR proficient PC, and post-platinum therapy.
STATEMENT OF SIGNIFICANCE
We define therapeutic strategies that target subgroups of PC using novel signatures of DNA damage response deficiency and replication stress. This potentially offers patients with DNA repair defects therapeutic options outside standard of care platinum chemotherapy and is being tested in clinical trials on the Precision-Panc platform.
INTRODUCTION
Pancreatic Cancer (PC) has recently overtaken breast cancer to become the third leading cause of cancer death in the USA 1 and is predicted to become the second within a decade 2 .
Pancreatic ductal adenocarcinoma (PDAC), the more common form of PC, is dominated by mutations in four well-known cancer genes (KRAS, TP53, CDKN2A and SMAD4). Only a few genes are mutated in 5 -15% of cases, amidst an ocean of infrequently mutated genes in the majority of patients [3] [4] [5] [6] [7] [8] [9] [10] [11] . This diversity may explain the lack of progress with targeted therapies, as actionable genomic events being targeted therapeutically are present in only a small proportion of unselected participants in clinical trials 12 . To better select patients to clinical trials, biomarkers that predict response to novel, and established treatments are urgently needed and must extend beyond the detection of point mutations in coding genes and low prevalence actionable genomic events.
Whilst molecular subtyping of cancer based on biological attributes can facilitate drug discovery, to be clinically relevant, the optimal taxonomy must inform patient management through prognostication or more importantly, treatment selection 13 . Recent studies have subtyped PC in various ways 5, 9, [14] [15] [16] [17] [18] , grouping similarities based on structural attributes of genomes, genes mutated in pathways, or molecular mechanisms inferred through mRNA expression. Despite discrepancies in nomenclature, one molecular class (variably termed quasi-mesenchymal, basal-like or squamous) is consistently defined and is associated with a poor prognosis 19, 20 . These biologically based molecular taxonomies of PC, whilst associated with differences in outcome, are yet to inform treatment decisions.
DNA damage response (DDR) deficiency is a hallmark of cancer, including PC 8 , which is thought to render some tumors preferentially sensitive to DNA damaging agents such as platinum. There is a growing compendium of novel therapeutics that target DNA damage response mechanisms and the cell cycle such as ATR and WEE1 inhibitors 21 . Genomic instability, a key feature of many cancers, typically secondary to defects in DNA replication and repair during the cell cycle often results in replication stress 22, 23 . Oncogene activation drives replication stress, particularly through RAS and MYC signaling, both of which are prevalent molecular features of PC 22, 24, 25 . The platinum containing regimen, FOLFIRINOX, has become the standard of care for all stages of PC, yet is only suitable for patients with good performance status, however the majority of patients unfortunately do not respond [26] [27] [28] . Consequently, many patients suffer the morbidity, and even mortality, of systemic platinum chemotherapy with little or no survival benefit or quality of life. Biomarker driven patient selection strategies, and novel therapeutics that build on platinum response or disease stabilization that target DDR mechanisms, provide a substantial opportunity to improve outcomes.
Here we use 61 patient-derived cell lines (PDCL) of PC (Supplementary Table 2 ), to define subtype-specific molecular mechanisms and identify opportunities for molecular subtypedirected treatment selection that targets DDR mechanisms. We performed mRNA expression analysis (RNAseq) (n = 48) complemented with whole genome sequencing (n = 47), which was further enhanced with Reverse Phase Protein Arrays (RPPA), functional screens using small interfering RNA (siRNA) and targeted functional analysis. We identify novel biomarkers of DDR deficiency and replication stress with potential clinical utility that associate with therapeutic sensitivity. We show that DDR deficiency exists independently of replication stress, the previously identified poor prognostic Squamous subtype is enriched for replication stress and transcriptomic readouts of replication stress confer sensitivity to therapeutics that target the cell cycle checkpoint machinery.
RESULTS

Patient-derived cell lines recapitulate PC subtypes
We recently defined four transcriptomic subtypes of PC 5, 19 , with two distinct primary lineages, termed Classical Pancreatic (which can be further divided into Pancreatic Progenitor, Immunogenic and Aberrantly Differentiated Endocrine eXocrine subtypes) and Squamous. A key distinction is the epigenetic profile of the Squamous subtype, with chromatin modification and methylation orchestrating the loss of pancreatic endodermal transcriptional networks, and as a consequence, suppressing transcripts that designate a pancreatic identity 5 (Figure 1a ). Hierarchical clustering of RNAseq data from the 48 PDCLs recapitulated the two primary classes of PC ( Supplementary Figure 1 ). Twenty-eight (58%) of the PDCLs were classified as Squamous, and 20 (42%) were Classical (Supplementary Table 5 ). The preservation of the 26 transcriptional networks (Gene Programs) we previously described in bulk PC 5 was compared to PDCL derived gene programs ( Supplementary Figure 1 , Supplementary tables 13 and 14). In total, 17 of the 26 Gene programs were closely recapitulated in the PDCLs ( Supplementary Figure 1) , with the expected absence of immune infiltrate related transcriptional networks (Supplementary Tables 14) . The lack of stroma permitted higher resolution of epithelial transcriptomic networks, revealing key mechanisms that are difficult to discern form biopsy samples.
Differential expression of genes related to DNA damage response, cell cycle control and morphogenic processes were observed between subtypes and correlated in both PDCLs and bulk tumor samples ( Figure 1a ). These findings suggest that PDCLs are representative of bulk PC and can be used to develop novel therapeutic strategies for the clinic, and that epithelial cell purity can provide greater sensitivity in detecting aberrant mechanisms.
Defining DDR deficiency in PDCLs of Pancreatic Cancer
Various biomarkers of DDR deficiency associated with therapeutic response have been proposed, but not validated and not used clinically in PC. Genomic markers of DDR deficiency such as a high ranking COSMIC BRCA point mutational signature co-segregates with high prevalence of structural variants, termed the 'unstable' genomic subtype, and deleterious mutations in homologous recombination repair (HR) pathway genes such as BRCA1 and 2 and PALB2 4 ( Figure 1b ). We previously demonstrated that these signatures associate with clinical response to platinum in PC 4 . More recently, early data also suggest a therapeutic signal using PARP inhibitors, however, efficacy is not well defined beyond Supplementary Table 10 ). Out of 47 PDCLs with WGS data, 6 (13%) had a positive HRD signature, 9 (19%) had > 200 SVs (unstable genome), 10 (21%) had mutations in DDR genes of which 2 were germline variants (both in BRCA2) (Figure 1b , Supplementary Table 11 ). There were 4 PDCLs with homozygous mutations in either BRCA1, BRCA2 or RPA1, and these were all associated with unstable genomes, and 3 of these were HRD signature positive (Figure 1b , Supplementary Table 3 ).
Significant overlap existed amongst these, with n = 3 PDCLs with all 4 biomarkers present, n = 1 had 3 (unstable genome, HRD signature, BRCA mutational signature) biomarkers positive, n = 4 were positive for 2 biomarkers and the remaining n = 8 had 1 biomarker positive ( Supplementary Table 3 ).
DDR deficiency co-segregates with response to Platinum and PARP inhibitor treatment
To investigate the relationship between these putative biomarkers of DDR deficiency and Platinum and PARP inhibitor response, cell viability assays were performed on 15 PDCLs.
PDCLs defined as DDR deficient were more sensitive to both Cisplatin therapy (P = 0.031) and PARP inhibition (P < 0.001) compared to DDR proficient PDCLs (Figure 2 , Supplementary Table 11 ). The DDR deficient PDCLs all had EC50s to platinum of below the sensitivity threshold (10µM) set by large scale pan-cancer cell line drug screens (n = 880) using Cisplatin (cancerrxgene.org (COSMIC)). These results suggest that DDR deficiency, as defined by these putative biomarkers have potential clinical utility in predicting response to platinum treatment. Importantly, this included both somatic and germline mutations, suggesting that therapeutic sensitivity extends beyond germline BRCA1 and 2 mutations ( Figure 2 , Supplementary table 11 ).
To further define clinically applicable therapeutic response biomarkers of DDR deficiency in vivo, bulk tumor PDX models that represent both DDR proficient (PDX 2133) and deficient (PDX 2179) PC were generated in balb/c nude mice. The DDR proficient PDX did not respond to DNA damaging agents, including Cisplatin and the PARP inhibitor Olaparib combination ( Figure 2 ). The DDR deficient PDX model, with a bi-allelic somatic BRCA1 mutation, responded exceptionally to Cisplatin and Olaparib as monotherapy, and in combination ( Figure 2 ), suggesting PARP inhibition can be as effective as Platinum chemotherapy in DDR deficient PC.
Replication Stress is a feature of the Squamous subtype of PC
Replication Stress has been described to be closely related to DDR deficiency. As a consequence, we investigated subtype specific targeting of replication stress as a novel therapeutic strategy. We found significant subtype differences in the expression of genes controlling cell cycle, including the G2/M checkpoint in both PDCLs and bulk tumor PC ( Figure 1 ). Expression of WEE1 (P = 0.006), CDK6 (P = 0.02) and CDK7 (P < 0.001) was enriched in the squamous subtype in both PDCLs and bulk tumor ( Figure 1a ). We then used a combination of DNA maintenance, replication and cell cycle regulation network related transcriptional profiles from Gene Ontology (GO) and pathway enrichment analysis to define replication stress using mechanisms associated with DNA replication (ATR activation, chromosomal maintenance, E2F transcriptional pathways, homologous recombination, Fanconi anemia, base-excision repair, p53 signaling, ER stress, and RNA processing). This resolved into a transcriptomic signature (termed the Replication Stress signature) which was applied as a hypothetical biomarker of replication stress (Figure 3 , Supplementary Table 12 ).
PDCLs with high replication stress were more likely to be of squamous subtype (P < 0.001) ( Figure 3 ) and had significantly higher levels of pRPA at rest (a surrogate marker of singlestranded DNA break accumulation which infers replication stress) (P < 0.0001) ( Figure 3 ).
PDCLs with high replication stress and concurrent HR deficiency had a greater proportion of γH2AX positive cells at rest (a marker of double-stranded DNA breaks) (P = 0.0086) and had persistently high levels of pRPA and γH2AX positive cells at 20 hours after ionizing radiation, when pRPA and γH2AX should have returned to normal levels in cells with no replication defects and competent at repairing this level of DNA damage (Supplementary Figure 4 ). These data demonstrate the squamous subtype is enriched for genes associated with replication stress, potentially secondary to oncogene activation, and provides a potential novel therapeutic strategy.
Replication Stress is associated with sensitivity to Cell Cycle Checkpoint inhibitors
Differential expression of genes regulating the G2/M checkpoint in PDCLs and bulk tumors (such as WEE1 and CHEK1) and the dependence on ATR activation in response to replication stress ( Figure 3a ) suggest that selective inhibition of these mechanisms may confer efficacy in tumors with high replication stress.
Further supporting this hypothesis, we performed an siRNA screen targeting genes controlling DNA damage repair and replication demonstrated a functional dependency on DNA damage response proteins, including ATM, ATR and CHK1 in squamous PDCLs (FIGURE 4a, Supplementary Figure 2 ). This is in keeping with the results from the immunofluorescent and RPPA analyses suggesting higher baseline levels of proteins associated with replication stress in the squamous PDCLs and a subsequent dependency on these proteins and cell cycle checkpoints for maintaining genomic integrity and cell survival.
Novel agents currently in early phase clinical trial targeting the cell cycle was used to generate a therapeutic testing strategy ( Figure 4b ) [34] [35] [36] [37] [38] . Based on these data, in-vitro sensitivity was assessed using cell viability assays after a selection of PDCLs were treated with increasing doses of inhibitors of CHK1 (AZD7762), CDK4/6 (Palbociclib) and PLK4 (CFI-400945) demonstrating differential sensitivity ( Supplementary Figure 4 ). Based on promising early clinical trial results in other cancer types [37] [38] [39] [40] [41] [42] , more extensive testing using inhibitors of ATR (AZD6738) and WEE1 (AZD1775) was performed on 15 PDCLs defined as high and low replication stress based on the replication stress signature score ( Figure   3a , Supplementary Figure 4 ). This demonstrated that PDCLs with high replication stress were more sensitive to both ATR and WEE1 inhibition (Figure 4c -f). Importantly, these responses were independent of DDR status ( Supplementary Figure 4 ), suggesting replication stress status is a more reliable marker of therapeutic response to ATR and WEE1 inhibition.
Replication Stress is independent of DDR deficiency in PC
To further investigate the relationship of replication stress and DDR deficiency and the alignment of these therapeutic segments, a comparison was performed using the PDCL cohort. Using the described biomarkers of DDR deficiency and Replication Stress, a two by two grid was constructed to compare replication stress ranking and DDR deficiency ( Figure   5 ). This demonstrated that signatures of DDR deficiency and replication stress are largely independent of each other, yet high replication stress is enriched in the squamous subtype (P = 0.007) ( Figure 5 ). Therapeutic response data was overlapped based upon previously described experiments using ATR / WEE1 inhibitors and platinum, generating biomarker hypotheses for therapeutic responsiveness ( Figure 5 ). PDCLs that are DDR deficient with high replication stress respond to both DDR targeting agents (e.g. Platinum and PARP inhibitors) and cell cycle checkpoint inhibitors (e.g. ATR and WEE1 inhibitors); DDR deficient, low replication stress to DDR agents only; DDR proficient, high replication stress to cell cycle checkpoint inhibitors only; and DDR proficient, low replication stress to neither class of agent ( Figure 5 ).
Potential Clinical utility of the Replication Stress signature
To assess the potential clinical validity and utility of these pre-clinical data, the relationship between the replication stress signature score and molecular subtypes in bulk tumor samples was assessed using published transcriptomic data sets of PC 5 , 9 . This included whole transcriptome sequencing sets acquired through the International Cancer Genome Consortium (ICGC), totaling 94 patients with primary resected PC ( Figure 6 ). This recapitulated the association between squamous molecular subtype and high replication stress (P = 0.006) ( Figure 6 , Supplementary Figure 5 ), with 50% of squamous tumors in the top quartile of tumors ranked by the replication stress score.
The replication stress signature was then applied to The Cancer Genome Atlas (TCGA) 9 high epithelial cellularity set (ABSOLUTE purity ³0.2), and the ICGC micro-array transcriptomic data sets (Supplementary Figure 5) . Again, the top-ranking quartile of replication stress signature was significantly enriched with squamous subtype PC (TCGA set P = 0.009, micro-array set P = 0.037) (Supplementary Figure 5 ). We then examined the potential clinical utility of the replication stress signature in biopsy material acquired through Olaparib. This was as effective as Cisplatin monotherapy, or combination treatment using Cisplatin and Olaparib suggesting that in appropriately selected patients, PARP inhibitor monotherapy can potentially induce clinically relevant responses similar to platinum. This provides potential therapeutic options for patients with poor performance status, or after intolerance or acquired resistance to platinum has developed 30 . Predicting platinum response is more complex than using point mutations in DDR genes and the COSMIC BRCA mutational signature alone. Structural variation signatures, including > 200 SVs 4 and the SV pattern HRD signature appear to be robust, but require testing in clinical settings.
We define a novel replication stress signature, which is associated with the squamous subtype in PDCLs and bulk tumors from multiple PC cohorts (n = 383 patients). Elevated replication stress, as defined by this signature, is associated with functional deficiencies in In summary, we develop and perform pre-clinical testing on novel biomarkers of DDR deficiency and replication stress which have potential clinical utility. Well-designed precision oncology platforms, such as Precision-Panc (precisionpanc.org), will enable biomarker driven clinical testing and allow refinement of biomarkers predicting meaningful responses and potential translation into clinical practice. Cell culture. Patient derived cell lines (PDCLs) were generated as previously described 4, [44] [45] [46] .
Materials and methods
PDCLs were cultured in conditions specifically formulated for each individual line based on growth preferences and those resulting in cell lines that most closely resembled physiological cells from the initial tumor. Detailed culture media formulations are given in Supplementary Material Table 1 . Cells were grown in a humidified environment with either 5% or 2% CO 2 at 37° (Supplementary Material Table 2 ). All cell lines were profiled by short tandem repeat (STR) DNA profiling as unique (CellBankaustralia.com). Cell lines were tested routinely for mycoplasma contamination using TBST)(Cell Signalling Technologies) for 30 mins, 3 x 5 min washes with TBST, 1 x 5 min wash with dH20, slides spun at 2000rpm for 5mins and allowed to air dry in the dark. An additional slide was stained with FAST Green FCF for normalization against total protein: 3 x 5min washes with dH20, incubated for 15 mins in 1% NaOH, slides rinsed 20 x in dH20, incubated for 10 min in dH20, incubated in de-stain (30% methanol, 7% glacial acetic acid, 63% dH20) for 15 min, incubated for 3 mins in FAST green staining solution (0.0025%w/v FAST green in de-stain), rinsed 20 x in dH20, incubated for 15 mins in de-stain solution, rinsed 20 x in dH20, spun at 2000rpm for 5 mins and allowed to air dry in the dark. All steps were performed at room temperature with agitation. Slides were visualized using an Innopsys 710AL infra-red microarray scanner and signals quantified using MAPIX microarray image analysis software (Innopsys). Non-specific signals were determined by omitting the primary antibody incubation step. All signals were within the linear range of detection with an R 2 vlaue >0.9. Final output is the median value for each dilution series, background subtracted and normalized for protein loading.
In Vitro Cytotoxicity assays. Cells were seeded on 96 well plates (Costar®, Corning Incorporated) and allowed to adhere for 24 hours. Cells were treated with increasing doses of Cisplatin (Accord γH2AX and pRPA foci formation assay. PDCLs were cultured as standard and seeded in 96 well plates at a concentration of 10 4 cells per well. At 24 hours after seeding, cells were either left untreated or exposed to 4 Gray (Gy) ionizing radiation (IR) and processed for analysis at 2, 4 and 20 hours after exposure. Cells were stained with primary antibodies at a dilution of 1:1000 with anti-pRPA32 (S4/S8, Bethyl Laboratories Inc.) and anti-γH2AX (Ser139, MERCK). Secondary antibodies used were Alexa 488 anti-mouse IgG (green) and Cy3 anti-rabbit IgG (Sigma). DAPI (Life Technologies) was used as a nuclear stain. Confocal imaging was performed using the Opera Phenix TM high content screening system (PerkinElmer) at 63x magnification using a water objective, at wavelengths of 405nm (DAPI), 488nm (Alexa) and 561nm (Cy3). A minimum of 320 cells (median Identification and verification of structural variants. The Somatic structural variant pipeline were identified using the qSV tool. A detailed description of its use has been recently published 4, 47 .
Identification of and verification of point mutations.
Substitutions and indels were called using a consensus calling approach that included qSNP, GATK and Pindel. The details of call integration and filtering, and verification using orthogonal sequencing and matched sample approaches are as previously described 4, 47, 48 .
Mutational signatures. Mutational signatures were defined for genome-wide somatic substitutions, as previously described 4 . siRNA screening. Prior to siRNA screening, optimal cell number per well and optimal reverse transfection reagents for each PDCL were identified by assessing transfection efficiency, using six different transfection reagents (Dharmafect 1-4, RNAimax, Lipofectamine 2000) , using the manufacturers' instructions. Experimental conditions were selected that met the following criteria: (i) compared to a mock control (no lipid, no siRNA), the transfection of non-silencing negative control siRNA caused no more than 20 % cell inhibition; (ii) compared to non-silencing negative control siRNA, the transfection of PLK1-targeting siRNA caused more than 80% cell inhibition; (iii) cell confluency reached 70% within the range of 4-7 days. The later criteria allowed assays to be terminated whilst cells were in growth phase. Once optimal conditions were established, each PDCL was reverse transfected in a 384 well-plate format with a custom siGENOME siRNA library (Dharmacon, USA) designed to target 714 kinase coding genes, 256 protein phosphatase coding genes, 722 genes implicated in energy metabolism, 73 tumor suppressor genes and 166 genes involved in the repair of DNA damage ( Supplementary Table 19 for list of genes covered in the siRNA library). Each well in the 384 well-plate arrayed library contained a SMARTpool of four distinct siRNA species targeting different sequences of the target transcript. Each plate was supplemented with non-targeting siCONTROL and siPLK1 siRNAs (Dharmacon, USA). Cell viability was estimated five days after transfection using a luminescent assay detecting cellular ATP levels (CellTitre-Glo, Promega). Luminescence values were processed using the cellHTS2 R package. To evaluate the effect of each siRNA pool on cell viability, we log2 transformed the luminescence measurements and then centred these to the median value for each plate. The plate-centred data were scaled to the median absolute deviation (MAD) of the library as a whole to produce robust Z-scores. All screens were performed in triplicate. Screens judged to have poor dynamic range (Z' factor < 0) or poorly correlated replicates (r < 0.7) were excluded during an evaluation of screen quality. Z scores were adjusted using a quantile normalization. siRNA screen analysis. siRNA "hits" were identified by calculating the median absolute deviation of normalized Z-scores for a given siRNA across all samples and identifying sample Z scores greater than or equal to 2 x the median absolute deviation. This analysis generated a "seed" matrix (n siRNA hits x m samples) which was used as starting input for the Randon Walk with Restart (RWR) algorithm as implemented by the R package dnet. This algorithm was used to identify functionally important subnetworks associated with cell viability from a curated protein-protein interaction network STRING v 10. Considering the complex nature of topological features of human interactome data, we introduce a randomization-based test to evaluate the candidate interactors utilizing 1000 topologically matched random networks. Candidate interactors that remain significant (i.e., p edge<0.05) were identified and a consensus subnetwork was constructed by collapsing all sample-specific results. The resulting network was visualized using RedeR.
RNAseq analysis. RNA-seq read mapping was performed using the bcbio-nextgen project RNAseq pipeline (https://bcbio-nextgen.readthedocs.org/en/latest/). Briefly, after quality control and adaptor trimming, reads were aligned to the GRCh37 genome build using STAR Counts for known genes were generated using the function featureCounts in the R/Bioconductor package "Rsubread". The R/Bioconductor package "DESeq2" was used to normalize count data between samples and to identify differentially expressed genes. Expression data were normalized using the rlog transform in the DESeq2 package and these values were used for all downstream analyses.
WGCNA analysis.
Weighted gene co-expression network analysis (WGCNA) was used to generate a transcriptional network from rlog normalized RNAseq data. Briefly, WGCNA clusters genes into network modules using a topological overlap measure (TOM). The TOM is a highly robust measure of network interconnectedness and essentially provides a measure of the connection strength between two adjacent genes and all other genes in a network. Genes are clustered using 1-TOM as the distance measure and gene modules are defined as branches of the resulting cluster tree using a dynamic branch-cutting algorithm. Full methods can be found in the supplementary material.
Identification of significant subtype specific changes in pathways and/or processes. The R package clipper was used to identify pathways and/or processes showing significant change between PDCL subtypes. clipper implements a two-step empirical approach, employing a statistical analysis of means and concentration matrices of graphs derived from pathway topologies, to identify signal paths having the greatest association with a specific phenotype. Pathway analysis. Ontology and pathway enrichment analysis was performed using the R package 'dnet' and/or the ClueGO/CluePedia Cytoscape plugins as indicated. Visualisation and/or generation of network diagrammes was performed using either Cytoscape or the R package RedeR.
Homologous Recombination Signature generation. Signature generation was done using WGS data as previously described 31, 32 . A positive signature was defined as if samples had > 50
SVs and % deletions, duplication or translocations > 70, and structural variation pattern was not focal (ie large number of SVs not due to chromothripsis or amplifications). Plus, either the predominant variant types were deletions and translocations and the median deletion size was < 10kb OR the predominant variant type was duplication and the median duplication size was < 50 kb.
Replication Stress signature generation. Differentially expressed genes were compared to genes associated with gene ontology (GO) terms using the R package 'dnet'. Significantly expressed GO terms involved in DNA damage response and cell cycle control were selected. Differential expression of each selected GO term was applied to each individual PDCL that underwent RNA sequencing. This in turn, was used to generate a composite score by totaling the score for each selected GO term. The 'sig.score' function from the R package genefu was used to calculate a specific signature score in a given sample using the signatures generated for each pathway and/or process. This was termed the replication stress signature. Generation of signature score for bulk tumor samples followed the same methodology Bulk expression sets and immune signature scores. Bulk RNAseq expression data, subtype assignments and immune signature scores were obtained from Bailey et al 5 .
Gene set enrichment of PDAC subtypes. Gene set enrichment was performed using the R package 'GSVA'. Gene sets representing PDAC subtypes were generated as previously described.
Clustering and subtype assignment. The package 'ConsensusClusterPlus' was used to classify PDCLs according to the expression signatures defined in Moffitt et al. 18 and Bailey et al. 5 Gene sets representing PDAC subtypes were generated as previously described.
Statistical analysis.
A Kruskal-Wallis test was applied to the indicated stratified scores to determine whether distributions were significantly different. Fisher's exact tests were used to evaluate the association between dichotomous variables. Plot generation. Heatmaps and oncoplots were generated using the R package ComplexHeatmap.
Dotcharts, density plots and boxplots were generated using the R package ggpubr. Violin plots were generated using the python package Seaborn. Biplot was generated using the R package ggfortify.
All other plots were generated using the R package ggplot2. DDR deficiency is a hierarchical score which incorporates the COSMIC BRCA mutational signature (signature 3), the number of structural variants distributed across the genome, and the HRD signature associated with BRCA deficiency. The combination of high/low states of each characteristic result in 4 groups. Squamous subtype PDCLs (blue squares) are associated with high replication stress (P = 0.007, Chi-squared). PDCLs tested are identified and encircled blue. DDR deficiency, and the replication stress signature predicted differential therapeutic response. 
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